Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.45 |
| ▸ | AXL | P30530 | 4/20 | 0.45 |
| ▸ | STK17B | O94768 | 2/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448151 | 0.96 | AXL (0.46) | STK17AAXLSTK17BPAK1BRD4 | |
| SCHEMBL3461367 | 0.91 | STK17A (0.46) | STK17AAXLSTK17BEGFRERBB2 | |
| SCHEMBL3448179 | 0.90 | STK17A (0.47) | STK17AAXLSTK17BCSNK2A1FGFR1 | |
| SCHEMBL3448660 | 0.90 | AXL (0.53) | STK17AAXLSTK17BPAK1BRD4 | |
| SCHEMBL3449696 | 0.87 | EGFR (0.46) | STK17AAXLSTK17BBRD4EGFR | |
| SCHEMBL3451722 | 0.86 | MEN1 (0.46) | STK17AAXLSTK17BPAK1CSNK2A1 | |
| SCHEMBL3450813 | 0.86 | AXL (0.46) | STK17AAXLSTK17BCSNK2A1EGFR | |
| SCHEMBL13310831 | 0.86 | STK17A (0.51) | STK17AAXLSTK17BEGFRMAP3K8 | |
| SCHEMBL3448587 | 0.85 | STK17A (0.50) | STK17AAXLSTK17BPAK1CSNK2A1 | |
| SCHEMBL3447211 | 0.85 | STK17A (0.51) | STK17ASTK17BCSNK2A1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885AXL 2812/4885STK17B 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.